Q4 FY25 Earnings Presentation February 26, 2026 © Solventum 2026. All rights reserved. Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain forward-looking information about Solventum's financial results and estimates and business prospects, including guidance for 2026, that contain or incorporate by reference statements that relate ...

Core Insights - The report identifies key sectors with positive earnings forecasts for 2025, focusing on companies that are expected to outperform based on growth metrics and other indicators [2] - The report highlights the performance of various industries, with construction materials and oil & petrochemicals showing significant growth in the past year [2][3] Industry Performance - The top-performing industries in January, March, and over the past year include: - Comprehensive: 13.2%, 33.4%, 83.9% - Construction Materials: 8.9%, 28.6%, 49.5% - Oil & Petrochemicals: 7.1%, 28.0%, 41.1% - Coal: 5.9%, 9.1%, 21.8% - Communication: 4.1%, 27.6%, 73.0% [2] - The bottom-performing industries include: - Retail: -5.6%, 3.4%, 10.1% - Non-ferrous Metals: -5.0%, 39.2%, 115.5% - Pharmaceutical Biology: -4.1%, -0.2%, 11.5% - Computer: -3.7%, 6.4%, 1.9% - Non-bank Financials: -2.4%, 3.8%, 9.1% [2] Company-Specific Insights - Yingke Medical (300677.SZ) is identified as a core beneficiary in the nitrile glove industry recovery, with expectations of a price increase and improved supply-demand dynamics [4] - The company is projected to achieve net profits of 1.71 billion and 2.19 billion in 2026 and 2027, respectively, with corresponding P/E ratios of 15.0 and 11.8 [5] Real Estate Sector Analysis - The report notes that the Hong Kong real estate sector saw an overall increase during the Spring Festival, with specific stocks showing varied performance [6] - Investment recommendations for the real estate sector include a focus on companies with strong land acquisition and sales performance, particularly in first and second-tier cities [6]

Core Viewpoint - Zhonghong Medical (300981) has shown a mixed performance in terms of stock price and financial results, with a recent stock price increase but declining profits and revenues in the latest quarterly report [1][3]. Group 1: Stock Performance - As of February 10, 2026, Zhonghong Medical's stock closed at 13.54 yuan, up by 3.28%, with a turnover rate of 2.05% and a trading volume of 80,700 shares, amounting to a total transaction value of 109 million yuan [1]. - On the same day, the net inflow of main funds was 14.4651 million yuan, accounting for 13.26% of the total transaction value, while retail investors saw a net outflow of 11.2646 million yuan, representing 10.33% of the total [1]. Group 2: Financing and Margin Trading - In the financing and margin trading segment, on February 10, 2026, the financing buy amounted to 20.7183 million yuan, with a financing repayment of 11.4878 million yuan, resulting in a net financing increase of 9.2305 million yuan [2]. - The margin trading data indicates that 4,100 shares were sold short, with no shares being repaid, leaving a short balance of 35.52 million yuan and a total margin trading balance of 127 million yuan [2]. Group 3: Financial Performance - According to the Q3 2025 report, Zhonghong Medical's main revenue for the first three quarters was 1.864 billion yuan, reflecting a year-on-year increase of 1.38%, while the net profit attributable to shareholders was -7.2102 million yuan, a decline of 114.13% [3]. - The third quarter alone saw a revenue of 626 million yuan, down by 9.24% year-on-year, with a net profit of -12.9531 million yuan, a decrease of 170.01% [3]. - The company reported a debt ratio of 28.02%, investment income of 8.7618 million yuan, financial expenses of -17.6741 million yuan, and a gross profit margin of 10.54% [3].

Core Viewpoint - The company, ZhenDe Medical, has decided to cancel repurchased shares and reduce its registered capital, impacting its total share capital and registered capital amounts. Group 1: Share Repurchase and Capital Reduction - The company will cancel a total of 1,959,310 shares, which includes 129,442 shares already repurchased and 1,829,868 shares from the second phase of the employee stock ownership plan that have not been unlocked. This change will alter the total share capital from 265,835,535 shares to 263,876,225 shares and reduce the registered capital from 265,835,535 yuan to 263,876,225 yuan [1][2]. Group 2: Notification to Creditors - Creditors are notified that they have 30 days from receiving the notice, or 45 days from the announcement date if no notice is received, to claim their debts or request guarantees. Failure to act within this timeframe will not affect the validity of their claims, and the company will continue to fulfill its obligations as per the original debt agreements [2]. Group 3: Debt Claim Submission Requirements - Creditors must provide original and copies of documents proving the existence of the debt relationship when submitting claims. Legal entities must also present their business license and identification of their legal representative, while individuals must provide valid identification [3]. Group 4: Debt Claim Submission Methods - Claims can be submitted in person, by mail, or via email. The submission period starts from February 10, 2026, and lasts for 45 days. Contact details for submissions include a physical address, phone number, and email [4][5].

Key Points - The stock price of Zhonghong Medical (300981) closed at 12.93 yuan on February 5, 2026, with a slight increase of 0.31% and a turnover rate of 0.6% [1] - The trading volume was 23,600 shares, with a total transaction amount of 30.4488 million yuan [1] Trading Information Summary - On February 5, 2026, the net inflow of main funds was 232,200 yuan, while the net inflow of speculative funds was 1.8918 million yuan; retail investors experienced a net outflow of 2.124 million yuan [1][3] Company Announcement Summary - Zhonghong Medical held its first extraordinary general meeting of shareholders for 2026 on February 5, 2026, where three proposals were approved: 1. Investment of idle self-owned funds in low-risk financial products for 2026 2. Conducting foreign exchange derivative trading for 2026 3. Engaging in commodity futures hedging business and related transactions for 2026 - All proposals were passed with the related shareholders abstaining from voting on the related transaction proposal [1][3] - A legal opinion from Beijing Deheng Law Firm confirmed the legality and validity of the meeting's procedures and voting results [1]

Financial Data and Key Metrics Changes - In Q1 fiscal year 2026, Embecta generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [15] - GAAP gross profit for Q1 2026 totaled $161.7 million with a margin of 61.9%, compared to $151.7 million and 60% in the prior year [19] - GAAP net income for Q1 2026 was $44.1 million, with earnings per diluted share of $0.74, compared to zero in the prior year period [22] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7% due to continued insourcing by Becton Dickinson [18] Market Data and Key Metrics Changes - U.S. revenue for Q1 totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis, driven by lower pricing and volumes [15] - International revenue for Q1 totaled approximately $130 million, representing an increase of 8.4% on a reported basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is in the seed growth phase, focusing on staying competitive in core markets, selectively expanding the portfolio, and building financial flexibility through disciplined capital allocation [7] - A significant initiative is the brand transition to establish Embecta as an independent company, with over 95% of U.S. and Canadian revenue transitioned to the Embecta brand [8] Management's Comments on Operating Environment and Future Outlook - Management expects the recovery in China to be more weighted towards the second half of the fiscal year, with ongoing market dynamics impacting performance [16] - The company reaffirmed its financial guidance for the year, now expecting to be closer to the lower end of the guidance ranges due to incremental U.S. pricing headwinds [18][25] Other Important Information - The company is collaborating with over 30 pharmaceutical partners on GLP-1 therapies, with several partners already selecting Embecta as a supplier [10] - The company expects to generate between $180 million and $200 million in free cash flow for 2026, although closer to the low end of that range [26] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in the U.S. driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [31][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [43] Question: Can you elaborate on the GLP-1 opportunity and the impact of oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that oral therapies are expanding the market rather than pulling patients away from injectables [36][39]

Financial Data and Key Metrics Changes - In the first quarter of fiscal year 2026, the company generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [15] - GAAP gross profit and margin for the first quarter totaled $161.7 million and 61.9%, compared to $151.7 million and 60% in the prior year period [19] - GAAP net income and earnings per diluted share were $44.1 million and $0.74 during the first quarter, compared to 0 in the prior year period [22] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7% due to the continued insourcing of these products by Becton Dickinson [18] Market Data and Key Metrics Changes - U.S. revenue for the quarter totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis [15] - International revenue for the first quarter totaled approximately $130 million, representing an increase of 8.4% on a reported basis and an increase of 4.6% on an adjusted constant currency basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is focused on transitioning to a broader medical supplies company and drug delivery partner, building on its foundation as a leader in global insulin delivery [8] - The brand transition initiative aims to establish Embecta as an independent company, with over 95% of U.S. and Canadian revenue transitioned to the Embecta brand [9] - The company is advancing its GLP-1 strategy, collaborating with over 30 pharmaceutical partners, and expects initial generic GLP-1 launches in markets such as Canada, Brazil, China, and India beginning in calendar year 2026 [11] Management's Comments on Operating Environment and Future Outlook - Management expects to be closer to the lower end of the financial guidance ranges due to incremental U.S. pricing headwinds, while the international business outlook has improved [18][25] - The company anticipates a recovery in China in the second half of the year, with ongoing market dynamics and geopolitical factors impacting performance [32] Other Important Information - The company generated approximately $17 million in free cash flow during the first quarter and repaid approximately $38 million of outstanding debt, reducing net leverage to approximately 2.8 times [24] - The company reaffirmed its financial guidance for fiscal year 2026, expecting revenue to be flat to down 2% compared to 2025 levels [25] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in U.S. revenue driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [30][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [42][43] Question: Can you elaborate on the GLP-1 opportunity and the impact of new oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that the market for orals is expanding rather than pulling patients away from injectables [36][39]

Core Viewpoint - The company, Weijian Medical, is focusing on a dual business model of "medical + consumer" for high-quality development, with a clear strategic direction for the next three years and a detailed operational plan for 2026 [1] Group 1: Strategic Direction - The company aims to achieve high-quality development through "product leadership, excellent operations, brand enhancement, and digital empowerment" [1] - The revenue strategy includes steady progress towards goals set by equity incentives, while profitability will be enhanced through product innovation, structural optimization, channel improvement, cost reduction, and brand building [1] Group 2: Investment Value - The core investment value is reflected in five aspects: broad industry space for both main businesses, a focus on improving profitability, mutual empowerment of dual brands, low debt ratio with ample cash flow, and a commitment to long-termism and ESG development [2] - The company has distributed a total cash dividend of 2.88 billion yuan and repurchased shares for 690 million yuan, representing 100.3% of the net amount raised from the initial public offering by mid-2025 [2] Group 3: Medical Sector Development - The medical sector is positioned as the foundation for growth, with a core goal of "decisive growth" by leveraging both organic growth and external acquisitions [2] - The company plans to optimize product structure, promote high-margin products, and expand into overseas markets and various domestic channels [2] - The acquisition of the U.S. company GRI will enhance access to quality overseas channels and customer resources, with a focus on Southeast Asia and the Middle East by 2026 [2] Group 4: Profitability and Brand Strategy - The medical sector's profitability is recovering post-public health events, with operating profit margins on the rise due to a shift towards high-end and branded products [3] - The consumer sector, represented by the brand "Cotton Era," leverages its medical background and quality to attract a loyal customer base, focusing on product categories related to maternal and infant care, personal care, and home sleep products [3] - The brand strategy includes a comprehensive online and offline channel layout, with an emphasis on partnerships with mainstream e-commerce platforms and refined store operations for rapid channel growth [3] Group 5: Long-term Commitment - The company is committed to executing its established development strategy and aims to achieve its set goals while ensuring shareholder interests through stable dividends and strong operational performance [4]

Core Viewpoint - The company announced a change in the project quality reviewer for its 2025 financial audit, appointing Wang Wen as the new reviewer following the adjustment of the previous reviewer, Zheng Chuanxian [2][4]. Group 1: Change of Project Quality Reviewer - The company received a letter from Tianjian regarding the change of the project quality reviewer, with Wang Wen replacing Zheng Chuanxian due to the latter's work adjustment [2]. - Wang Wen has been a certified public accountant since 2011 and has been involved in auditing listed companies, including providing audit services for the company since 2025 [3]. Group 2: Independence and Integrity Record - Wang Wen has no violations of the independence requirements as per the Chinese Certified Public Accountant Independence Standards and has not faced any criminal or administrative penalties in the last three years [4]. - The transition of responsibilities during this change has been orderly, ensuring that the change will not adversely affect the company's 2025 financial statement audit and internal control audit [4].

Group 1 - The core viewpoint of the article highlights that Zhonghong Medical (300981) is facing significant financial challenges, with a projected net loss for 2025 ranging from 130.5 million to 87 million yuan [1][3] - The expected net profit, excluding non-recurring losses, is projected to be between 186.5 million and 124.5 million yuan, primarily impacted by the protective glove industry's cyclical nature, price fluctuations, and currency exchange rates [1][3] - The company anticipates asset impairment provisions, including fixed assets and inventory, amounting to approximately 27 million to 41 million yuan, and goodwill impairment provisions of about 58 million to 88 million yuan [1][3] Group 2 - On January 30, 2026, Zhonghong Medical's stock closed at 12.77 yuan, down 1.39%, with a turnover rate of 0.86% and a trading volume of 33,800 shares, resulting in a transaction amount of 42.9834 million yuan [1] - The main capital flow on January 30 showed a net outflow of 2.7059 million yuan from institutional investors and a net inflow of 2.9078 million yuan from retail investors [1][3] - The company announced that its subsidiary, Beijing Linpu Medical Supplies Co., Ltd., has opened a special account for raised funds at Bank of Hangzhou's Beijing branch and signed a regulatory agreement to ensure proper management of the raised funds [1][3]